Daphne Quimi - 02 Jan 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role: Chief Financial Officer
Signature: /s/ Christian Formica, Attorney-in-Fact
Issuer symbol: FOLD
Transactions as of: 02 Jan 2023
Net transactions value: -$287,464
Form type: 4
Filing time: 04 Jan 2023, 18:13:21 UTC
Previous filing: 03 Oct 2022
Next filing: 06 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FOLD	Common Stock	Tax liability	$185,165	-15,165	-4.5%	$12.21	320,147	02 Jan 2023	Direct
transaction	FOLD	Common Stock	Award	$0	+73,508	+23%	$0.000000	393,655	03 Jan 2023	Direct	F1
transaction	FOLD	Common Stock	Tax liability	$102,300	-8,575	-2.2%	$11.93	385,080	03 Jan 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FOLD	Stock Options (right to buy)	Award	$0	+130,480		$0.000000	130,480	03 Jan 2023	Common Stock	130,480	$11.93	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2024 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F2	These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.